Introduction
Moyamoya disease is usually identified through a combination of clinical suspicion and vascular imaging. The condition is characterized by progressive narrowing or blockage of the arteries at the base of the brain, especially the internal carotid arteries and their main branches. As these vessels become narrowed, the brain develops a network of small collateral blood vessels to compensate. On imaging, this network can resemble a hazy cloud, which is the reason for the name “moyamoya,” a Japanese term meaning “something hazy like a puff of smoke.”
Accurate diagnosis matters because Moyamoya disease can lead to ischemic stroke, transient ischemic attacks, intracranial hemorrhage, seizures, and cognitive decline if it is not recognized. The disorder can also occur as part of a broader syndrome or secondary to another disease process, in which case the management approach may differ. Doctors therefore aim not only to detect the arterial changes but also to determine whether the pattern fits primary Moyamoya disease or a Moyamoya syndrome caused by another condition.
Recognizing Possible Signs of the Condition
The first clue is often a neurologic event caused by abnormal brain blood flow. In children, the disease commonly presents with transient weakness, speech difficulty, involuntary movements, or episodes triggered by hyperventilation, crying, or fever. Reduced cerebral blood flow during these physiologic stresses can produce brief, reversible symptoms. In adults, the first presentation may be an ischemic stroke, a transient ischemic attack, or less commonly a brain hemorrhage caused by fragile collateral vessels.
Symptoms vary with age because the disease can affect the brain differently at different stages of life. Children more often show signs of reduced blood supply, while adults may present with either ischemia or bleeding. Some patients have headaches, cognitive slowing, seizures, sensory changes, or visual disturbances. However, symptoms alone do not diagnose Moyamoya disease. They only indicate that the cerebral circulation may be compromised and that imaging of the brain vessels is warranted.
Medical History and Physical Examination
Diagnosis begins with a careful history. Clinicians ask when symptoms started, whether they are transient or persistent, whether they are triggered by exertion or changes in breathing, and whether there has been a prior stroke or seizure. They also ask about developmental delays in children, migraine-like headaches, episodes of weakness on one side of the body, speech problems, or changes in school performance and behavior that could reflect chronic underperfusion of the brain.
A family history is important because Moyamoya disease can cluster in families and may have a genetic contribution. Doctors also ask about conditions associated with Moyamoya syndrome, such as sickle cell disease, neurofibromatosis type 1, Down syndrome, prior cranial radiation, thyroid disease, or autoimmune disorders. These associated conditions can point toward a secondary cause of the vessel narrowing.
The physical examination focuses on the nervous system. A clinician checks strength, reflexes, sensation, gait, coordination, speech, eye movements, and mental status. During or after a stroke-like episode, abnormalities may be found on one side of the body or in language function. In children, the examination may also reveal developmental concerns or evidence of recurrent subtle ischemic events. Blood pressure, cardiac findings, and signs of systemic disease are also reviewed because the differential diagnosis extends beyond the brain itself.
Diagnostic Tests Used for Moyamoya disease
Imaging is central to diagnosis, but several types of tests may be used together. The goal is to show the characteristic arterial narrowing, assess the collateral circulation, evaluate whether the brain has already suffered injury, and identify other disorders that could explain the findings.
Magnetic resonance imaging (MRI) of the brain often provides the first major evidence of disease. MRI can show old or recent infarcts, white matter injury, microbleeds, or regions of chronic ischemia. It does not by itself fully confirm Moyamoya disease, but it shows the effect of poor blood supply and helps determine the extent of brain injury.
Magnetic resonance angiography (MRA) visualizes the blood vessels noninvasively. It can demonstrate narrowing of the distal internal carotid arteries, the proximal anterior cerebral arteries, and the proximal middle cerebral arteries. It may also show the abnormal collateral vessels that develop as compensation. MRA is particularly useful as an initial vascular study, especially in children, because it avoids ionizing radiation and catheterization.
Computed tomography angiography (CTA) is another noninvasive way to image the cerebral vessels. CTA can define stenosis, occlusion, and collateral channels, and it may be used when MRI is not available or when rapid evaluation is needed. In an acute stroke setting, CT-based studies may be the practical first step. CTA offers excellent anatomic detail, although it involves radiation and iodinated contrast.
Catheter cerebral angiography, also called digital subtraction angiography, remains the reference standard for confirming Moyamoya disease. In this test, a catheter is advanced into the cerebral arteries and contrast dye is injected while images are taken in sequence. The study shows the exact pattern and severity of arterial narrowing, the characteristic basal collateral network, and the degree of blood flow redistribution. It is especially valuable before surgical treatment because it maps the vessels in detail and helps surgeons plan revascularization.
Laboratory tests are not used to diagnose Moyamoya disease directly, but they are important for finding associated conditions or alternative causes of vascular disease. Common studies may include a complete blood count, inflammatory markers, coagulation studies, autoimmune screening, thyroid testing, and tests for sickle cell disease or other hematologic disorders when appropriate. In a patient with stroke symptoms, labs also help exclude metabolic causes and assess overall health before imaging or surgery.
Functional brain perfusion tests assess how well blood reaches different parts of the brain. Techniques may include perfusion MRI, perfusion CT, single-photon emission computed tomography, or positron emission tomography. Some centers use tests with vasodilatory challenge, such as acetazolamide, to determine whether the brain has exhausted its ability to increase blood flow. These studies are useful because Moyamoya disease is not just an anatomic narrowing; it is a disorder of cerebral perfusion reserve. A brain region may appear structurally intact yet be at high risk for ischemia under stress.
Electroencephalography (EEG) may be ordered when seizures are suspected or when episodes are difficult to characterize. EEG does not diagnose Moyamoya disease, but it can detect abnormal electrical activity caused by ischemic injury or seizure tendency secondary to the vascular disorder.
Tissue examination is not routinely needed to diagnose Moyamoya disease, but pathology may occasionally be available if surgery or another procedure yields tissue samples. Histologic findings may show changes in affected arteries, including intimal thickening and thinning of the media, along with fragile collateral vessels. These findings support the vascular diagnosis, but they are not usually required because imaging is typically sufficient.
Interpreting Diagnostic Results
Doctors diagnose Moyamoya disease when imaging shows progressive stenosis or occlusion at the terminal portions of the internal carotid arteries and the proximal arteries of the anterior circulation, together with the development of an abnormal collateral network at the brain base. The classic angiographic appearance is bilateral but can be unilateral in early or limited disease. The diagnosis becomes more secure when the imaging pattern matches the clinical picture of transient ischemia, stroke, seizure, or hemorrhage.
Interpretation also depends on excluding other causes. If the vascular changes are present because of an underlying disorder such as sickle cell disease or neurofibromatosis, the patient may be classified as having Moyamoya syndrome rather than primary Moyamoya disease. This distinction is important because the underlying condition can influence prognosis and treatment planning.
Perfusion studies add another layer of interpretation. A patient may have severe arterial narrowing yet still maintain adequate resting perfusion through collaterals. In that case, reduced perfusion reserve on stress testing suggests a limited ability to compensate and a higher risk of future ischemic events. MRI evidence of prior infarcts, chronic white matter injury, or microhemorrhage supports the diagnosis and helps estimate disease burden.
Conditions That May Need to Be Distinguished
Several disorders can mimic Moyamoya disease or create similar imaging findings. Atherosclerotic disease can narrow the intracranial arteries, particularly in adults with vascular risk factors, but it usually does not produce the classic basal collateral network in the same pattern. Vasculitis can also cause vessel narrowing, but inflammatory markers, clinical context, and angiographic appearance may point toward an inflammatory process rather than Moyamoya disease.
Other conditions that may be considered include vasospasm, arterial dissection, congenital arterial anomalies, and radiation-induced vasculopathy. In children, sickle cell disease is a major alternative explanation because it can produce Moyamoya-like changes. Autoimmune and genetic syndromes can also be associated with similar angiographic findings. Doctors distinguish these entities by combining imaging with history, laboratory evaluation, and the presence or absence of associated systemic signs.
It is also important to differentiate primary Moyamoya disease from Moyamoya syndrome. The vessel pattern may look similar on angiography, but the broader medical context determines whether the process is idiopathic or secondary to another disorder. That distinction affects both follow-up and treatment of contributing conditions.
Factors That Influence Diagnosis
Age strongly influences how the disease is recognized. Children often present with transient ischemic symptoms, developmental issues, or stroke triggered by stressors, while adults may present with hemorrhage or more obvious focal deficits. Because the presentation differs, the threshold for vascular imaging may also differ in pediatric and adult practice.
Severity and stage of disease influence which tests are most informative. Early disease may show subtle narrowing on noninvasive angiography, while advanced disease is more obvious and may require catheter angiography for definitive mapping. The presence of prior infarction, hemorrhage, or seizure can shape the diagnostic pathway because urgent neuroimaging may be needed first.
Related medical conditions also change the workup. When a child has sickle cell disease, or when an adult has autoimmune disease or prior radiation exposure, clinicians must consider secondary Moyamoya syndrome. This often prompts broader laboratory evaluation and a search for the underlying disorder. Family history may prompt consideration of genetic susceptibility, although a genetic result is usually supportive rather than definitive in routine clinical practice.
Conclusion
Moyamoya disease is diagnosed by recognizing a pattern: suggestive neurologic symptoms, careful clinical evaluation, and imaging evidence of progressive narrowing of the major arteries at the base of the brain with formation of fragile collateral vessels. MRI and MRA often provide the first major clues, CTA can clarify anatomy, and catheter angiography remains the most definitive test. Laboratory studies, perfusion imaging, and other evaluations help assess the broader medical context, measure the impact on blood flow, and rule out alternative explanations.
The diagnostic process is therefore both anatomical and functional. Doctors are not only looking for narrowed arteries, but also for the biologic consequences of reduced cerebral perfusion and the compensatory vessel network that defines the disease. Accurate diagnosis allows clinicians to distinguish primary Moyamoya disease from secondary causes and to determine the most appropriate treatment and follow-up.